Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
SILOSARASOTA, FL, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Allucent, a global full-service clinical research organization (CRO), to support the Company’s final preparations and planned submission of its investigational new drug application (IND) to the FDA for a Phase 1 clinical trial of its intranasal prophylactic SPC-15 as a treatment for PTSD. The Company currently expects to submit the IND in 2026 and commence its first-in-human (FIH) SPC-15 trial subsequent to FDA approval.
Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
SILO(NASDAQ:SILO) SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that IP Australia (the Australian Patent Office) has granted patent number 2020271839 to Silo’s research and licensing partner Columbia University for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress” exclusively licensed to Silo by Columbia University.
Silo Pharma Awarded US Biomarker Patent for Novel PTSD Therapeutic SPC-15
SILOSilo Pharma Approves Purchase Of Up To $1M Bitcoin As Treasury Reserve Asset
SILOSilo Pharma Enters Into Service Agreement With Resyca BV For Drug-Device Study Of Formulation-Specific Microchip-Based Nasal Spray System Used In PTSD Drug SPC-15
SILOSilo Pharma Completes Public Offering Of 3.33M Shares & Warrants At $0.60 Per Share, Raising $2M For Growth Initiatives
SILOSilo Pharma Prices Offering Of 3,333,338 Shares And Series A-1 Warrants At Combined Public Offering Price of $0.60; Gross Proceeds Of ~$2M
SILOSilo Pharma Engages Veloxity Labs For Bioanalytical IND-Enabling Study For Novel Intranasal PTSD Therapy, SPC-15
SILOSilo Pharma Agrees With Frontage Laboratories For FDA Requested 7-Day Safety And Toxicology Large Animal Study Of Lead Asset SPC-15, Intranasal Prophylactic Treatment For PTSD
SILOEXCLUSIVE: Silo Pharma's Investigational Ketamine Implant Hits All Endpoints In Pain Study In Animal Models
SILOSilo Pharma reported positive preclinical results for its ketamine-based implant SP-26, designed to treat chronic pain and fibromyalgia.
EXCLUSIVE: Silo Pharma Tells Benzinga 'Successfully demonstrates strong tolerability, sustained drug release and safety'
SILOEXCLUSIVE: Silo Pharma Tells Benzinga Co's SP-26 Ketamine Implant Meets All Endpoints In Fibromyalgia Study
SILOSilo Pharma Files Patent Application With USPTO For SPC-14, Intranasal Compound Exclusively Licensed AD Drug
SILOSilo Pharma Announces First Dosing In IND-Enabling GLP Study For SPC-15 In PTSD
SILOSilo Pharma Granted U.S. Patent For Novel Intranasal Post-Traumatic Stress Disorder Treatment Titled Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females
SILOSilo Pharma Files Provisional Patent Application For SPC-15 Combination Treatment
SILOSilo Pharma Announces Results From Preclinical Study On SPC-15, Highlighting Proposed Efficacy Of Combining SPC-15 With An NMDAR Antagonist
SILOSilo Pharma Reports Results in Sterilization And Dissolution Testing Of SP-26 Ketamine Implant, Showing Stability And Consistent 7-Day Drug Release
SILOSilo Pharma Reports Results From Study For Depression Treatment, Remission, and Relapse Prevention
SILO